NTM and Bronchiectasis: Research and Treatment Update | 3-25-2022 | Dialogue with a Doc series

Presented by:
Charles L. Daley, MD
Chief, Division of Mycobacterial & Respiratory Infections
Professor, Department of Medicine
National Jewish Health
Nontuberculous mycobacterial (NTM) infections, a non-contagious cousin of tuberculosis, has shown a marked increase in the U.S. population in recent years. Many NTM patients also develop bronchiectasis, a condition that inhibits the ability to naturally clear mucus and bacteria from the airways and puts individuals at ever-increasing risk of infection.

[@helentrammell766]

Learning about this condition helps understand the treatment, thank you.

[@HeyMJ.]

An excellent, relevant & current discussion that all can leverage to effectively communicate re pulmonary bronchiectasis, auto/immune involvement (Eg. RA; Allergy/Asthma), NTM v LTBI, and whether to treat or watch/wait. Team NJH, please know that your commitment to excellence in healthcare & pulmonary medicine is greatly appreciated. Thank You! 🕊

[@jennylinden3226]

Thank you for all the information gave me
Some hope

[@leonardeuler1018]

BCG is useful to treat or ameliorate MAC infection

[@lf9164]

What is BCG? I have this and it isn’t getting any better

[@elvishiekios8826]

@@lf9164Bacillus Calmette Guerin = vaccine against tuberculosis.